PRESS RELEASE:

.
Major funding boost granted for Proteus

07/12/17

.

It has been officially announced today that Proteus has been granted a major funding boost worth £3.8M to continue developing the healthcare research that is revolutionising how we diagnose and manage lung diseases.

.
Researchers from Proteus, SPHERE and I-Sense at the first EPSRC Healthcare Technology IRC conference in Bath, June 2017
.

Science Minister Jo Johnson has announced additional funding worth more than £11M for three Engineering and Physical Sciences Research Council (EPSRC) Interdisciplinary Research Collaborations (IRCs) – Proteus, SPHERE and I-Sense.

EPSRC’s IRCs are centres of internationally acknowledged scientific and technological excellence, bringing together researchers, clinicians, industry and other professionals to make a real impact in areas of key future industrial relevance to the UK.

Since receiving the initial £9.5 million EPSRC IRC grant in October 2013, Proteus has designed and constructed fully integrated multi-colour imaging platforms, which in combination with novel optical fibres and new detectors allow sensing, imaging and therapeutic interventions deep in the human lung.

In the first four years of the project the team have synthesised a range of chemical probes with the ability to detect and signal the presence of disease biomarkers including infection to enable the rapid and accurate diagnosis of bacterial infection, they have designed and fabricated a number of revolutionary detector chips as well as a camera that can ‘see’ through the body.

The next steps for the Proteus team are to take our technology into a new area in which different flavours of light can be used to diagnose disease, using the teams’ highly advanced light sensors that are able to count a single photon.

Proteus Director, Professor Mark Bradley, said: “We will bring together components and integrate them into a system that provides unprecedented sensitivity and specificity for disease diagnosis and therapy monitoring.

“In addition the proposal moves the IRC towards sustainability, creating a legacy from the EPSRC investment – accelerating the pathways to take new technology into patients, while developing commercial opportunities.”

In Proteus scientists, clinicians, project managers, regulatory, legal and business development expertise are all co-located in a real physical “hub” sharing an open plan office within the Queen’s Medical Research Institute adjacent to the Royal Infirmary of Edinburgh.

The IRC has become a beacon of excellence for Interdisciplinary research and co-location, and was cited as an exemplar as such to a recent House of Lords Life Sciences and Technology committee. Proteus has a strong translational agenda with multiple filed patents now under going active exploitation, while four compounds and a prototype system have entered first in-human studies.

As part of the “Next Steps” Programme, the Proteus IRC will establish a UK Healthcare Technology Accelerator Facility (HTAF) for current and future interdisciplinary projects both within Proteus and beyond.

This will include bring added expertise including health economics, care pathway analysis and trial design whilst leveraging the full range of skill-sets, academic, governance, regulatory and translational, required to progress engineering and physical sciences technology from across the UK, from bench to bedside, accelerating the commercial and clinical translation pathways.

Proteus will continue to be led by the University of Edinburgh with the team coming from the three founder institutions: the University of Edinburgh, the University of Bath and Heriot Watt University.

The University of Durham, who have been involved as a partner University, will now become the fourth member of the Proteus IRC. EPSRC Chief Executive, Professor Philip Nelson, said: “It is through innovative thinking and collaboration that we will address the biggest health and wellbeing issues facing society, and these three IRCs are the embodiment of that approach.

“They have already achieved a great deal in their first four years, and this additional funding will provide a springboard for them to realise yet more of their great potential and become thriving centres of excellence.”

When partner funding is included, almost £14 million is being invested in the three IRCs. He said: “This additional £11 million investment will enable vital collaborations to continue addressing many of the most pressing health and wellbeing issues, boosting the UK’s status as an innovation nation. 

“Research and development are central to building a Britain that’s fit for the future. Through our new Industrial Strategy and further investment of £2.3 billion, we are working with industry to remain at the cutting edge of scientific discovery.”

The three IRCs were initially established in 2013 with a £32 million investment by EPSRC. The IRCs Next Steps funding will support activities at the IRCs following the end of their current grants, in September 2018.

*

Particulars:

Led by: Professor Mark Bradley, University of Edinburgh

EPSRC grant: £3,800,000

Total grant value: £4,800,000

Partners: Durham University, University of Bath, Heriot-Watt University, UCL

*

Further Information:

For further information on any of the three IRCs mentioned, contact the EPSRC press office on 01793 444 044, or pressoffice@epsrc.ac.uk

View the official EPSRC press release here: http://bit.ly/2AAFPCH

To watch a video featuring researchers from Proteus, SPHERE and i-Sense talking about their cross-disciplinary research, visit Proteus’ Youtube channel (external site):  http://bit.ly/2nycOCL

To view a gallery of photographs taken at the EPSRC Healthcare Technology IRCs conference at the University of Bath, visit Proteus’ Flikr page (external site): https://flic.kr/s/aHskYNpHwV

.